SynthesisMedicine2025
Advances and prospects of CAR-T cell therapy in autoimmune disease treatment.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cellular therapies for rheumatic disease.Current opinion in rheumatology · 2026Review
- T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.Materials today. Bio · 2026Review
- Adapting CAR-T and CAR-Treg cancer therapies for autoimmunity: innovations and challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Autoimmune diseases, owing to their chronic onset and immune imbalance, seriously affect the quality of life of patients. Existing treatment methods have limited efficacy and significant side effects. Chimeric antigen receptor (CAR)-based cell therapy strategies, particularly CAR-T cell therapy, are emerging as a promising approach for treating autoimmune diseases. Therefore, this study systematically evaluated the application progress, safety, and target selection of CAR-T therapy in autoimmune diseases and clarified its clinical potential. Through a systematic review and analysis of clinical trial data on CAR-T cell therapy for autoimmune diseases worldwide, combined with target types, research stages, and trial status, a systematic analysis was conducted to explore the efficacy and safety of different targets and summarize the results of existing research. Early-stage studies account for the vast majority of relevant trials registered globally. CD19-targeting CAR-T cells have exhibited significant therapeutic effects in various autoimmune diseases, especially in difficult-to-treat cases. The research on new targets such as B cell maturation antigen and CD20 has also made positive progress. CAR-T cell therapy provides a potential new treatment option for autoimmune diseases, and the trend of diversified targets provides a new path for precision treatment, warranting further in-depth research and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.